Literature DB >> 23807364

Acute immune thrombocytopenic purpura as adverse reaction to oral polio vaccine (OPV).

Cheng-qiang Jin1, Hai-xin Dong, Zhuo-xiang Sun, Jian-wei Zhou, Cui-yun Dou, Shu-hua Lu, Rui-rui Yang.   

Abstract

A case of acute immune thrombocytopenic purpura following oral polio vaccine (OPV) is reported. An 82-d-old infant developed purpura at the same day after the second dose of oral polio vaccine. Until the time of hospital admission, the male infant had been in good health and had not received any drugs, and the possible causes of this condition were excluded. His platelet count was 13×10(9)/L. Platelet-associated IgG was elevated, but the amount of megakaryocytes in bone marrow aspirates was within the normal range, suggesting immune mechanism-associated thrombocytopenia. The infant recovered with the proper treatment within 30 d. Attention should be paid to OPV-associated thrombocytopenia, though it seems to be less frequent than after natural infections.

Entities:  

Keywords:  acute immune thrombocytopenic purpura; adverse reaction; immune thrombocytopenic purpura; infant; infection; oral polio vaccine; polio vaccine

Mesh:

Substances:

Year:  2013        PMID: 23807364      PMCID: PMC3906275          DOI: 10.4161/hv.24847

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  11 in total

1.  Countering the posteradication threat of smallpox and polio.

Authors:  D A Henderson
Journal:  Clin Infect Dis       Date:  2001-11-19       Impact factor: 9.079

2.  Type 2 polarized immune response holds a major position in Epstein-Barr virus-related idiopathic thrombocytopenic purpura (EBV-ITP).

Authors:  C-Q Jin; F Liu; H-X Dong; J Zhang; J-W Zhou; L Song; H Xiao; B-Y Zheng
Journal:  Int J Lab Hematol       Date:  2011-09-27       Impact factor: 2.877

3.  Progress toward interruption of wild poliovirus transmission - worldwide, 2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-05-14       Impact factor: 17.586

4.  Agranulocytosis and thrombocytopenic purpura following measles infection in a living-related orthotopic liver transplantation recipient.

Authors:  Y Arakawa; A Matsui; N Sasaki; T Nakayama
Journal:  Acta Paediatr Jpn       Date:  1997-04

Review 5.  Immune thrombocytopenic purpura: historical perspective, current status, recent advances and future directions.

Authors:  P Anoop
Journal:  Indian Pediatr       Date:  2012-10       Impact factor: 1.411

6.  Apropos risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.

Authors:  Subhash C Arya; Nirmala Agarwal
Journal:  Expert Rev Vaccines       Date:  2012-11       Impact factor: 5.217

Review 7.  Vaccine administration and the development of immune thrombocytopenic purpura in children.

Authors:  Valerio Cecinati; Nicola Principi; Letizia Brescia; Paola Giordano; Susanna Esposito
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

8.  Mechanical and thermal hyperalgesia in patients with poliomyelitis.

Authors:  Hatice Kumru; Enric Portell; Marti Marti; Sergiu Albu; Josep M Tormos; Joan Vidal; Josep Valls-Sole
Journal:  Clin Neurophysiol       Date:  2013-02-13       Impact factor: 3.708

9.  Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  D R Prevots; R K Burr; R W Sutter; T V Murphy
Journal:  MMWR Recomm Rep       Date:  2000-05-09

10.  Virus-associated immune thrombocytopenic purpura in childhood.

Authors:  Idil Yenicesu; Sevgi Yetgin; Emel Ozyürek; Deniz Aslan
Journal:  Pediatr Hematol Oncol       Date:  2002-09       Impact factor: 1.969

View more
  3 in total

Review 1.  Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases.

Authors:  Carlo Perricone; Fulvia Ceccarelli; Gideon Nesher; Elisabetta Borella; Qasim Odeh; Fabrizio Conti; Yehuda Shoenfeld; Guido Valesini
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

2.  Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine.

Authors:  Jackie M Helms; Kristin T Ansteatt; Jonathan C Roberts; Sravani Kamatam; Kap Sum Foong; Jo-Mel S Labayog; Michael D Tarantino
Journal:  J Blood Med       Date:  2021-04-06

3.  Trends of key surveillance performance indicators of acute flaccid paralysis: a descriptive analysis, Uganda, 2015-2020.

Authors:  Bob Omoda Amodan; Annet Kisakye; Patricia Thiwe Okumu; Sherry Rita Ahirirwe; Daniel Kadobera; Alfred Driwale; Alex Riolexus Ario
Journal:  BMC Public Health       Date:  2022-09-07       Impact factor: 4.135

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.